Advanced therapies in rare diseases



[ad_1]

"It's time to face (and win) some of the challenges that advanced therapies will bring to health, both in terms of the impact it will have on the health system organization. Italian, and more, on the care of patients.And for its large number of hospitals and research centers, Lombardy will be one of the regions most involved in these new challenges ": l & rsquo; OMAR (Observatory of Rare Diseases) presents the public discussion table on the role of Lombardy in the management of advanced therapies in the field of Rare Diseases, promoted for July 5 in Milan

  Detail of the hands of 39, a researcher at work "Until a few years ago the gene and cell therapies and the tissue engineering represented the future. Today we must talk about these techniques to the present day [1945] 9010] and it is time to face (and win) some of the challenges that advanced therapies will inevitably bring to health, particularly with regard to the impact they will have on the health of their loved ones. organization of the Italian health system and, even more, on patient management. The Lombardia because of the large number of hospitals and highly specialized research centers, will be one of the Regions to involve more in these new challenges. In this sense, it must meet the health needs of its residents, but also face a high mobility

patients from the rest of the country. Already in the past, the Lombard health system has faced similar situations through good practices that deserve to be studied and developed according to the additional evidence presented today by the study of new models of management ". OMAR (Observatory of Rare Diseases) presents the public discussion table entitled Advanced therapies in the field of Rare Diseases: Lombardy-Pilot Region in "value-based" management " promoted for on Thursday, July 5 to Milan (Napoleonic Hall of the University, Via Sant? Antonio, 12, 10-13), an event that will make use of the patronage of the Lombardy Region, of the AIEOP (Italian Association of Hematology and Pediatric Oncology), of the AISMME (Italian Association of Screening Hereditary Metabolic Diseases), the ATDL (Association Thalbademia Drepa nocitici Lombardi), the Maria Letizia Verga ONLUS commission, for the study and treatment of childhood leukemia, the Carlo Besta Foundation of the 39; IRCCS, Mario Negri of the IRCSS, REL (Lombard Hematology Network ie) and UNIAMO-FIMR (Italian Federation of Diseases) rare). (S.B.)

At this link the complete program is available. For more information and details: [email protected]

3 July 2018

Last updated: 3 July 2018 13:11

© All rights reserved

[ad_2]
Source link